Fig. 4
From: Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Mean difference in %∆PJPS between tofacitinib 5 mg BID and methotrexate in ORAL Start. Data demonstrate the mean differences in %∆PJPS for tofacitinib 5 mg BID at months 3, 6, and 12, minus the respective mean %∆PJPS for methotrexate in component joint pairs of the 68/66-joint count. %ΔPJPS, percentage change from baseline in PJPS; BID, twice daily; PJPS, paired joint pathology score